UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000053713
Receipt number R000061258
Scientific Title Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment
Date of disclosure of the study information 2024/03/04
Last modified on 2024/02/22 15:07:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment

Acronym

Preference Study on Treatment of HCV using DCE

Scientific Title

Patient and Physician Preferences for Treatment for Hepatitis C Virus Infection in Japan: A Discrete Choice Experiment

Scientific Title:Acronym

Preference Study on Treatment of HCV using DCE

Region

Japan


Condition

Condition

Hepatitis C Virus Infection

Classification by specialty

Hepato-biliary-pancreatic medicine Infectious disease Hepato-biliary-pancreatic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To elicit specific patient and physician preferences for treatment of HCV, which are important to maintain good adherence and work toward HCV elimination in Japan.

Basic objectives2

Others

Basic objectives -Others

To describe the proportion of each attribute of HCV treatment on the patient and physician perspectives.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Patient and physician preferences regarding HCV treatment.

Key secondary outcomes

Shared decision-making process for HCV treatment on patient and physician perspectives.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Participants must meet all the following inclusion/exclusion criteria.

[Patients]
1)Age 18 and above.
2)Individuals who self-report past or present HCV infection including 1) patients who have received drug therapy for HCV within the past 5 years and 2) patients who have never received any drug therapy for HCV but still presently have HCV.
3)Able to provide informed consent to participate in the study and willing to participate in the study.

[Physicians]
1)At least 3 years of clinical experience, including the period of clinical training.
2)Specializing in gastroenterology or gastroenterological surgery or general internal medicine.
3)Qualified as hepatologists by the Japan Society of Hepatology OR/AND gastroenterologists by the Japanese Society of Gastroenterology.
4)Having treated at least 1 patient with HCV and have prescribed drug therapy for HCV in the past.
5)Able to provide informed consent to participate in the study and willing to participate in the study.

Key exclusion criteria

[Patients]
1)Patients with suspected liver cirrhosis.
2)Patients with concomitant carcinoma.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Daisuke
Middle name
Last name Nakamoto

Organization

Gilead Sciences K.K.

Division name

Medical affairs-Liver Diseases Area

Zip code

100-6616

Address

16F GranTokyo South Tower, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan

TEL

03-6837-0055

Email

Daisuke.Nakamoto@gilead.com


Public contact

Name of contact person

1st name Michael
Middle name
Last name LOPRESTI

Organization

INTAGE Healthcare Inc.

Division name

Value & Access Department

Zip code

101-0062

Address

13F Ochanomizu SolaCity, 4-6 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan

TEL

050-3640-1444

Homepage URL


Email

m.lopresti@intage.com


Sponsor or person

Institute

Gilead Sciences K.K.

Institute

Department

Personal name



Funding Source

Organization

Gilead Sciences K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation TOUKEIKAI Kitamachi Clinic ERB

Address

1-1-3,Kichijoji-kitamachi,Musashino-shi,Tokyo,180-0001,Japan

Tel

03-6779-8116

Email

chi-pr-ec-kitamachi@cmicgroup.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 03 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 02 Month 07 Day

Date of IRB


Anticipated trial start date

2024 Year 03 Month 05 Day

Last follow-up date

2024 Year 03 Month 11 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Method: Web-based survey to investigate treatment preferences for HCV patients and physicians.
Utilize discrete choice experiments to measure treatment preferences.


Management information

Registered date

2024 Year 02 Month 26 Day

Last modified on

2024 Year 02 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061258


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name